Title: Increased survival with enzalutamide in prostate cancer after chemotherapy
Authors: Scher, Howard I ×
Fizazi, Karim
Saad, Fred
Taplin, Mary-Ellen
Sternberg, Cora N
Miller, Kurt
de Wit, Ronald
Mulders, Peter
Chi, Kim N
Shore, Neal D
Armstrong, Andrew J
Flaig, Thomas W
Fléchon, Aude
Mainwaring, Paul
Fleming, Mark
Hainsworth, John D
Hirmand, Mohammad
Selby, Bryan
Seely, Lynn
de Bono, Johann S
AFFIRM Investigators #
Contributors: Dumez, Herlinde
Issue Date: Sep-2012
Series Title: New England Journal of Medicine vol:367 issue:13 pages:1187-1197
Abstract: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science